ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
7 hedge funds and large institutions have $27.6M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 3 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
11% less capital invested
Capital invested by funds: $31M → $27.6M (-$3.41M)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MA
MYDA Advisors
Woodmere,
New York
|
-$94.1K |
| 2 |
Millennium Management
New York
|
-$55.6K |
| 3 |
HSBC Holdings
London,
United Kingdom
|
-$2.84K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Temasek Holdings
Singapore
| $11.4M | – | – | – |
|
|
PSCM
2
Prince Street Capital Management
New York
| $5.68M | – | – | – |
|
|
3
HSBC Holdings
London,
United Kingdom
| $4.53M | -$2.84K | -9 | -0.1% |
|
4
Baillie Gifford & Co
Edinburgh,
United Kingdom
| $3.46M | – | – | – |
|
|
PIM
5
Platinum Investment Management
Sydney Australia 2000,
Australia
| $2.27M | – | – | – |
|
|
6
Millennium Management
New York
| $258K | -$55.6K | -176 | -17% |
|
|
MA
7
MYDA Advisors
Woodmere,
New York
| $80K | -$94.1K | -298 | -54% |
|
ASLN Hedge Fund Activity: Q3 2018 in Review
7 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q3 2018, worth a combined $27.6M — down 11% from $31M a quarter earlier.
Fund positioning in ASLN was balanced in Q3 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 3 trimmed.
The largest seller was MYDA Advisors, cutting an estimated $94.1K.
- 7 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $27.6M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q3 2018, down 11% quarter-over-quarter.
- 0 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q3 2018 and 0 closed out.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q3 2018 was MYDA Advisors, an estimated $94.1K sold.
Based on aggregated 13F filings for Q3 2018.